Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
The purpose of this study is to find out if radiation therapy followed by intrathecal trastuzumab and pertuzumab is safe and will result in improved survival in HER2 positive breast cancer which has metastasized to the leptomeninges.
Phase I Primary Objective: - To determine the safety and MTD/recommended phase II dose (RP2D) of IT pertuzumab in combination with IT trastuzumab in the management of HER2+ breast LMD. Phase I Secondary Objectives: - To define the cerebrospinal fluid (CSF) pharmacokinetics (PK) of IT pertuzumab. - To evaluate the response rate (leptomeningeal and parenchymal) of IT trastuzumab/pertuzumab in the management of HER2+ breast LMD. - To evaluate PFS (leptomeningeal and parenchymal) following IT trastuzumab/pertuzumab in the management of HER2+ breast LMD. - To evaluate OS following IT trastuzumab/pertuzumab in the management of HER2+ breast LMD.
Herceptin (Trastuzumab); Pertuzumab (); Radiotherapy (); Trastuzumab (); rhuMAb HER2 (Trastuzumab)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.